Mpox: New mRNA Vaccine Versus Traditional Live Virus in Animal Series
MedCramPublished on September 9, 2024
Summary authored by editor@wellifi.com
TLDR Summary
Moderna's mRNA vaccine for EMPO shows promising results in early testing, joining other vaccines from Emergent BioSolutions and Bavarian Nordic. However, regulatory challenges have delayed vaccine distribution in affected regions.
Key Points
- Moderna's mRNA vaccine shows promise in early testing against EMPO.
- Emergent BioSolutions' AAM 2000 and Bavarian Nordic's Genios are two other vaccines under development.
- Logistical and regulatory challenges have delayed vaccine distribution in affected areas.
- Recent studies indicate that the mRNA vaccine may offer superior protection and lower morbidity rates.
Understanding the Latest Advances in EMPO Vaccines
In recent developments regarding the fight against EMPO (monkeypox), Moderna has announced promising results from their first mRNA vaccine trials. As highlighted in a recent update from MedCram, these advancements come at a crucial time when global health authorities are mobilizing resources to control outbreaks. In this article, we will explore the current landscape of EMPO vaccines, the different types of vaccines being developed, and the implications for public health.
The State of EMPO and Vaccine Development
Dr. Roger Schwelt, co-founder of MedCram, discusses the ongoing public health emergency declared by the WHO, aimed at coordinating international efforts to combat EMPO. In light of recent outbreaks, particularly in the Congo, the delivery of EMPO vaccines has faced significant delays due to regulatory hurdles and logistical challenges.
Challenges in Vaccine Distribution
As of late June, vaccine doses have started arriving in regions heavily affected by EMPO. However, regulatory approvals and logistical requirements have slowed down the deployment of these vaccines. The WHO has been pivotal in assessing the safety and efficacy of these vaccines, but delays in data submission have hampered swift authorization.
Types of EMPO Vaccines Under Development
Three primary types of vaccines are currently being explored for EMPO:
1. Emergent BioSolutions' AAM 2000
This live virus vaccine uses vaccinia, a virus that offers cross-protection against EMPO. Although it has been stockpiled as a response to potential bioterrorism threats, its use is limited due to concerns about side effects such as myocarditis.
2. Bavarian Nordic's Genios
This non-replicating live virus vaccine also utilizes vaccinia and has shown a good safety profile and efficacy rate of 60-70% against EMPO, making it a preferred option in high-risk populations.
3. Moderna's mRNA Vaccine
Moderna's vaccine employs lipid nanoparticles to deliver mRNA targeting conserved epitopes across orthopox viruses. Early studies suggest it may offer superior protection with lower morbidity rates compared to traditional vaccines.
Comparative Efficacy of EMPO Vaccines
Recent studies published in the Journal Cell compared the efficacy of Moderna's mRNA vaccine and Bavarian Nordic's MVA vaccine in non-human primates. Key findings include:
- Both vaccines resulted in zero mortality among vaccinated monkeys exposed to EMPO.
- Monkeys vaccinated with the mRNA vaccine exhibited significantly lower morbidity, with fewer pox lesions and less weight loss compared to control groups.
Current Recommendations and Future Directions
While these vaccines are not yet recommended for the general public in the United States, they are being prioritized for high-risk groups. Ongoing research and monitoring will determine their future use and availability.
Conclusion
The development of EMPO vaccines represents a significant leap in public health response to infectious diseases. As research continues and more data becomes available, the hope is that these vaccines can play a crucial role in controlling future outbreaks.
For more detailed updates and continuing medical education resources, visit MedCram.